A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer

J Smith, L Baer, S Blank, A Dilawari, K Carapetyan, M Alvear, M Utate, J Curtin, F Muggia, J Smith, L Baer, S Blank, A Dilawari, K Carapetyan, M Alvear, M Utate, J Curtin, F Muggia

Abstract

Introduction: We describe a screening and prevention programme primarily targeting under-served minority women at high risk of breast and/or ovarian cancer. Women attending this Bellevue Hospital Center (BHC) Clinic were either self-referred from a variety of special outreach programmes or referred internally by medical professionals caring for relatives or friends. Our objective was to delineate referral sources and preliminary risk-assessment findings in relation to demographic features in this population.

Methods: Following a detailed family and personal history intake and physical examination, each woman on her initial visit is categorized into a low (standard) risk, high-risk or indeterminate-risk group. Women found to be at high risk of developing breast and/or ovarian cancers are referred for further testing, additional screening measures, or participation in chemoprevention trials. All other women are counselled concerning follow-up and lifestyle issues.

Result: Between 2003 and 2007, 171 women for whom complete information was obtained were analysed. Thirty-four of the women were Caucasians (19.8%) and 137 (80.2%) were ethnically diverse minority women. Sixty-two (36.2%) were found to be at high risk with a median age of 42 years. The majority of the high-risk women were referred to the clinic by medical professionals (58%), most of whom were from within the BHC health care system. In fact, one-fourth of the referrals were women who carried a diagnosis of cancer, mostly arising in the breast, and who were concerned with risks to other family members. Trends in genetic testing results indicate fewer mutations among high-risk Asians than among other ethnicities.

Conclusion: Accurate risk assessments and implementation of screening and prevention measures have been challenging during the first few years of operation. Nevertheless, the need for providing consultation from internal referrals and the potential for genetic and psychosocial research in an ethnically diverse population are powerful incentives for continuing to evolve these services.

References

    1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77(11):2318–24. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>;2-Z.
    1. Satagopan JM, Offit K, Folkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2001;10(5):467–73.
    1. Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med. 2007;26(8):1775–87. doi: 10.1002/sim.2811.
    1. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24(6):863–71. doi: 10.1200/JCO.2005.03.6772.
    1. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25(20):2921–7. doi: 10.1200/JCO.2007.11.3449.
    1. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6. doi: 10.1126/science.1088759.
    1. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8(12):3776–81.
    1. Roa BB, Boyd AA, Volcik K, Richards SC. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14(2):185–7. doi: 10.1038/ng1096-185.
    1. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996;56(16):3663–5.
    1. Keyzer JF, Melnikow J, Kuppermann M, Birch S, Kuenneth C, Nuovo J, et al. Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview. Ethn Dis. 2005;15(3):395–406.
    1. Escobar-Chaves SL, Tortolero SR, MÇsse LC, Watson KB, Fulton JE. Recruiting and retaining minority women: findings from the Women on the Move study. Ethn Dis. 2002;12(2):242–51.
    1. Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, et al. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test. 2005;9(4):306–12. doi: 10.1089/gte.2005.9.306.
    1. Grann VR, Jacobson JS, Troxel AB, Hershman D, Karp J, Myers C, Neugut AI. Barriers to minority participation in breast carcinoma prevention trials. Cancer. 2005;104(2):374–9. doi: 10.1002/cncr.21164.
    1. Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, et al. A Prospective Study of Risk-Reducing Salpingo-oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer: Design and Baseline Characteristics: A Gynecologic Oncology Group Study. Cancer Epidemiol Biomarkers Prev. 2008;17:594–604.
    1. Berry DA, Iversen ES, Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701–12. doi: 10.1200/JCO.2002.05.121.
    1. Lindor NM, Lindor RA, Apicella C, Dowty JG, Ashley A, Hunt K, Mincey BA, Wilson M, Smith MC, Hopper J. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. Fam Cancer. 2007;6(4):473–82. doi: 10.1007/s10689-007-9150-z.
    1. Evans DG, Lalloo F, Wallace A, Rahman N. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet. 2005;42(7):e39. doi: 10.1136/jmg.2005.031989.
    1. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397–406. doi: 10.1200/JCO.2003.03.189.
    1. Barry K, Britt DW. Outreach: targeting high-risk women through community partnerships. Womens Health Issues. 2002;12(2):66–78. doi: 10.1016/S1049-3867(01)00134-7.
    1. Ricker C, Lagos V, Feldman N, Hiyama S, Fuentes S, Kumar V, et al. If we build it ... will they come?—establishing a cancer genetics services clinic for an underserved predominantly Latina cohort. J Genet Couns. 2002;15(6):505–14. doi: 10.1007/s10897-006-9052-5.
    1. Wilson BJ, Torrance N, Mollison J, Wordsworth S, Gray JR, Haites NE, et al. Improving the referral process for familial breast cancer genetic counseling: findings of three randomized controlled trials of two interventions. Health Technol Assess. 2005;9(3):iii–iv. 1–126.
    1. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541–8. doi: 10.1093/jnci/91.18.1541.
    1. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66. doi: 10.1093/jnci/93.5.358.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj